Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases - Poll - MDSpire

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

  • By

  • Xinhui Wang

  • Junyan Yu

  • May 28, 2026

  • 0 min

Share

Original Source(s)

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

  • by Xinhui Wang, Junyan Yu

  • May 28, 2026

Related Content

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer